Mitokinin is operates in the healthcare industry focusing on biotechnology business.

Mitokinin has advanced small molecule therapeutics that specifically increase the activity of active-form PINK1. Importantly, Mitokinin’s compounds do not interfere with the endogenous regulation of PINK1.

PINK1 is a master regulator of mitochondrial quality control. Mutations in PINK1 give rise to familial forms of Parkinson’s disease. Increased PINK1 activity rescues pathologies associated with neurodegenerative disease.

Mitokinin has an accomplished team of neuroscientists, chemists, pharmacologists, and administrative professionals all focused on our mission: delivering disease-modifying therapies for neurodegenerative disease.

Biotechnology

Health Care

Life Sciences

Mitokinin

Mitokinin's headquarters in San Francisco, CA, United States

Daniel De Roulet

Dara Ditsworth

Rishi Rakhit

Nicholas Hertz

Kevan Shokat

Ted Dawson

Miratul Muqit

Jean-Francois Trempe

Flint Beal

Michael D. Taylor

Peter Parker

Rana Al-Hallaq

Douglas Crawford

Description

People (4)

Jessica Li

Katharina von Löhneysen, Ph.D

Steven Hansberry

Tou Lee

Jobs